P-BCMA-ALLO1 is a novel investigational BCMA-targeted allogeneic, T stem cell memory (TSCM)-rich chimeric antigen receptor T-cell (CAR-T) therapy manufactured from healthy donor T-cells and available off-the-shelf. The findings presented at the AACR 2024 demonstrated that around 60% of patients (3 out of 5) with RRMM, who had advanced after receiving BCMA-targeted therapy, showed clinical improvements with P-BCMA-ALLO1. Furthermore, this investigational therapy exhibited favorable tolerability. Moreover, These latest findings further support the potential of the experimental off-the-shelf allogeneic CAR-T therapy as a viable option for a wider spectrum of multiple mye...
